Identification | Back Directory | [Name]
Win 54954 | [CAS]
107355-45-3 | [Synonyms]
Win 54954 5-{5-[2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy]pentyl}-3-methylisoxazole 5-[5-[2,6-Dichloro-4-[(4,5-dihydrooxazol)-2-yl]phenoxy]pentyl]-3-methylisoxazole | [Molecular Formula]
C18H20Cl2N2O3 | [MDL Number]
MFCD30594909 | [MOL File]
107355-45-3.mol | [Molecular Weight]
383.27 |
Chemical Properties | Back Directory | [Boiling point ]
555.4±50.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 100 mg/mL (260.91 mM; Need ultrasonic) | [form ]
Solid | [pka]
3.77±0.50(Predicted) | [color ]
White to off-white |
Hazard Information | Back Directory | [Uses]
WIN 54954 is an orally active and broad-spectrum antipicornavirus agent. WIN 54954 is effectiveness against human rhinovirus, echovirus 9 and enterovirus infections[1][2]. | [Definition]
ChEBI: WIN54954 is an aromatic ether. | [in vivo]
WIN 54954 (2-100 mg/kg; p.o.) protects 50% of the mice from developing paralysis following infection with coxsackievirus A-9 and echovirus-9 at the dose of 2 and 100 mg/kg, respectively[1]. | [References]
[1] Woods MG, et, al. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 1989 Dec;33(12):2069-74. DOI:10.1128/AAC.33.12.2069 [2] Fechner H, et, al. Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections. Molecules. 2011 Oct 11;16(10):8475-503. DOI:10.3390/molecules16108475 |
|
|